SPONSORED CONTENT
The 340B program continues to be a central topic of discussion in the pharmaceutical landscape, especially as specialty medications become an increasing portion of healthcare spending. Specialty pharmacies, covered entities (CEs), and manufacturers are navigating a complex environment shaped by regulatory updates, financial
…